Orgenesis Inc. Stock price
Is Orgenesis Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,133 stocks worldwide.
Key metrics
Orgenesis Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Orgenesis Inc. forecast:
Analyst Opinions
7 Analysts have issued a Orgenesis Inc. forecast:
Don't miss a Thing! We will send you all news about Orgenesis Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
| Head office | United States |
| CEO | Ms. Caplan |
| Employees | 146 |
| Founded | 2008 |
| Website | www.orgenesis.com |


